Enanta Pharmaceuticals, Inc. Announces Submission Of EU Marketing Authorization Applications To European Medicines Agency For All-Oral, Interferon-Free Hepatitis C Regimen Containing ABT-450
5/8/2014 7:59:09 AM
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that AbbVie, Enanta’s collaboration partner for ABT-450, has submitted Marketing Authorization Applications (MAA) to the European Medicines Agency (EMA) seeking approval for its investigational, all-oral, interferon-free regimen for the treatment of adult patients infected with chronic genotype 1 (GT1) hepatitis C virus (HCV).
Help employers find you! Check out all the jobs and post your resume.
comments powered by